Menu
Search Clinical Trials
Back to Search Results
Study Complete
Astellas Study ID
8062-CL-2002

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 with a Single Dose of Morphine in Recreational Opioid Using Participants

Astellas Study ID
NCT04448561
Clinicaltrials.gov ID
NCT04448561
EUCTIS ID
N/A
EudraCT ID
N/A
jRCT ID
N/A
CN CDE ID
N/A
Get more information

Study summary

The primary purpose of this study was to assess the safety and tolerability of multiple doses of ASP8062 or placebo alone and in combination with a single dose of morphine.

This study also assessed the potential for pharmacokinetic interaction between ASP8062 and morphine.

Additional Study Details

Phase
1
Product
  • ASP8082
  • morphine
  • Placebo
    • Type
    Interventional
    Masking
    Double (Participant, Investigator)
    Enrollment number
    24
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Download Document(s)
    Plain Language Summary
    Available Language(s): English
    Download Document(s)
    Protocol and Statistical Analysis Plan
    Available Language(s): English
    Download Document(s)

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 with a Single Dose of Morphine in Recreational Opioid Using Participants? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Republic of Moldova
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Former Serbia and Montenegro
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Republic of Korea
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Altasciences Clinical Kansas, Inc.
      Overland Park, KS, United States, 66212
      Contact Us
      Trial info
      Follow Trial
      Age
      18 - 60 years
      Diamond icon
      Condition
    • Opioid Drug Abuse
      • Gender icon
      Sex
      Female & Male
      Calendar icon
      Trial Dates
      Jun 2020 - Sep 2020
      Additional Study Details
      Inclusion Criteria

        Inclusion Criteria:

      • Participant is a recreational opioid user who has used opioids for nontherapeutic (recreational) purposes on at least 10 occasions within their lifetime, with at least 1 opioid use in the last 90 days.
      • Participant has a body mass index (BMI) range of 18 to 36 kg/m^2, inclusive and weighs at least 50 kg at screening.
      • Female participant is not pregnant and at least 1 of the following conditions apply:
        • Not a woman of childbearing potential (WOCBP)
        • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 28 days after final investigational product (IP) administration.
      • Female participant must agree not to breastfeed starting at screening and throughout the study period and for 28 days after final IP administration.
      • Female participant must not donate ova starting at first dose of IP and throughout the study period and for 28 days after final IP administration.
      • Male participant with female partner(s) of childbearing potential (including breastfeeding partner[s]) must agree to use contraception throughout the treatment period and for 90 days after final IP administration.
      • Male participant must not donate sperm during the treatment period and for 90 days after final IP administration.
      • Male participant with a pregnant partner(s) must agree to remain abstinent or use a condom with spermicide for the duration of the pregnancy throughout the study period and for 90 days after final IP administration.
      • Participant agrees to not participate in another interventional study while participating in the present study.

        • Exclusion Criteria:

      • Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
      • Participant has any condition which makes the participant unsuitable for study participation.
      • Female participant who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening.
      • Participant has a known or suspected hypersensitivity to ASP8062 or morphine and/or other opioids, or any components of the formulations used.
      • Participant has had previous exposure with ASP8062.
      • Participant has any of the liver function tests (alkaline phosphatase [ALP], alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase and total bilirubin [TBL]) ≥ 1.5 × upper limit of normal (ULN) on day -1. In such a case, the assessment may be repeated once.
      • Participant has any clinically significant history of allergic conditions (including drug allergies, asthma or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to first IP administration.
      • Participant has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal and/or other major disease or malignancy with exception of history of cholecystectomy.
      • Participant has a history of moderate or severe use disorder for any substance other than caffeine or tobacco (based on the Diagnostic and Statistical Manual of Mental Disorders, edition 5 (DSM-5) criteria).
      • Participant has a history or presence of any clinically significant psychiatric disorders such as, bipolar 1, schizophrenia, schizoaffective disorder or major depressive disorders.
      • Participant has had recent suicidal ideation within the last 12 months or participant who is at significant risk to commit suicide using the Baseline/Screening Columbia-suicide severity rating scale (C-SSRS) at screening and the Since Last Visit C-SSRS on day -1.
      • Participant has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 1 week prior to day -1.
      • Participant has any clinically significant abnormality following an investigator’s review of the physical examination, ECG and protocol-defined clinical laboratory tests at screening or on day -1.
      • Participant has a mean pulse < 50 or > 90 bpm; mean systolic blood pressure > 150 mmHg; mean diastolic blood pressure > 95 mmHg (measurements taken in duplicate after participant has been resting in the supine position for at least 5 minutes) on day -1. If the mean blood pressure exceeds the limits above, 1 additional duplicate may be taken.
      • Participant has a mean corrected QT interval using Fridericia’s formula (QTcF) of > 450 msec (for male participants) and > 470 msec (for female participants) on day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG may be taken.
      • Participant has a positive test for amphetamines, barbiturates, benzodiazepines, cocaine, phencyclidine, alcohol and/or opiates on day -1. Positive tetrahydrocannabinol is not exclusionary and a cannabis intoxication evaluation will be performed. Participant may be reconsidered.
      • Participant has used any prescribed or nonprescribed drugs (including vitamins and natural and herbal remedies, e.g., St. John’s Wort) in the 2 weeks prior to first IP administration, except for occasional use of acetaminophen (up to 2 g/day), topical dermatological products, including corticosteroid products, hormonal contraceptives and hormone replacement therapy (HRT).
      • Participant must be willing to abstain from smoking (including use of tobacco-containing products and nicotine or nicotine-containing products [e.g., electronic vapes]) from at least 1 hour predose through at least 8 hours postdose on days 9 and 10.
      • Participant has used any inducer of metabolism (e.g., barbiturates and rifampin) in the 3 months prior to day -1.
      • Participant has had significant blood loss, donated approximately 500 mL of whole blood (excluding plasma donation) within 56 days prior to screening or donated plasma within 7 days prior to day -1.
      • Participant has a positive serology test for hepatitis B surface antigen, hepatitis C virus antibodies or antibodies to human immunodeficiency virus (HIV) type 1 and/or type 2 at screening.
      • Participant has loss of ability to freely provide consent through imprisonment or involuntary incarceration for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
      • Participant is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      Find a Trial
      2

      Why are Clinical Trials Important?

      Learn More
      3

      Why Participate in a Clinical Trial?

      Discover More

      For Your Information

      THE PURPOSE OF THIS WEBSITE IS TO OFFER EDUCATION AND INFORMATION TO PATIENTS AND THEIR FAMILIES AND FRIENDS, THE PUBLIC, AND HEALTHCARE PROFESSIONALS ABOUT THE CLINICAL TRIAL PROCESS. IN ADDITION, THE WEBSITE WILL PROVIDE SPECIFIC INFORMATION ABOUT ASTELLAS CLINICAL TRIALS. PLEASE READ THE COMPLETE ASTELLAS TRANSPARENCY POLICY TO LEARN ABOUT THE CLINICAL TRIAL INFORMATION AVAILABLE ON THIS WEBSITE